Small Molecule and Biotechnology-Based Therapeutics for Neurology-Focused Companies: 2021’s IPOs Part V

This article is Part 5 of a review series covering all the initial public offerings for the biotech and pharmaceutical industries in 2021. Part 1 and Part 2 provided an overview of 2021 IPOs by therapy area, technology, and therapeutic class. Part 3 and Part 4 provided a deep dive into the 2021 IPOs for oncology-focused companies developing conventional small molecules and biotechnology-based therapeutics. 

This short article takes a deeper look into the small molecule and biotechnology-based therapeutics being developed by  companies focused on central nervous system (CNS) indications (i.e. therapeutics targeting neurological and psychiatric disorders) and other neurological conditions like pain that IPO’d in 2021, including:

• Companies by asset class and primary indication

• Lead molecules, mechanisms of action, and structures where available

• Development stage at IPO

• IPO proceeds

• A company spotlight